|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Bayside Health |
|---|---|
| Information provided by: | Bayside Health |
| ClinicalTrials.gov Identifier: | NCT00163982 |
Purpose
This study is looking at the detection of vasoactive peptides in portal hypertension.
| Condition | Intervention |
|---|---|
|
Portal Hypertension |
Drug: Norfloxacin |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
Contacts and Locations| Contact: William W Kemp, MBBS, FRACP | 92762000 ext 3327 | w.kemp@alfred.org.au |
| Australia, Victoria | |
| Alfred Hospital | Recruiting |
| Melbourne, Victoria, Australia, 3181 | |
| Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au | |
| Principal Investigator: | William W Kemp, MBBS, FRACP | The Alfred |
More Information
| Study ID Numbers: | AH4204 |
| Study First Received: | September 13, 2005 |
| Last Updated: | July 25, 2007 |
| ClinicalTrials.gov Identifier: | NCT00163982 History of Changes |
| Health Authority: | Australia: Human Research Ethics Committee |
|
HVPG > 12 mmHg |
|
Anti-Infective Agents Liver Diseases Norfloxacin Molecular Mechanisms of Pharmacological Action Vascular Diseases Enzyme Inhibitors Hypertension, Portal |
Pharmacologic Actions Anti-Bacterial Agents Digestive System Diseases Therapeutic Uses Cardiovascular Diseases Nucleic Acid Synthesis Inhibitors Hypertension |